Brian McKelligon - 08 Jul 2025 Form 4 Insider Report for Akoya Biosciences, Inc. (AKYA)

Role
President and CEO, Director
Signature
/s/ Brian McKelligon
Issuer symbol
AKYA
Transactions as of
08 Jul 2025
Net transactions value
$0
Form type
4
Filing time
10 Jul 2025, 20:40:22 UTC
Previous filing
25 Mar 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
McKelligon Brian President and CEO, Director C/O AKOYA BIOSCIENCES, INC., 100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH /s/ Brian McKelligon 10 Jul 2025 0001857447

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKYA Common Stock Other +393,338 +94% 813,464 08 Jul 2025 Direct F1, F2
transaction AKYA Common Stock Other +331,090 +41% 1,144,554 08 Jul 2025 Direct F1, F2
transaction AKYA Common Stock Tax liability -196,866 -17% 947,688 08 Jul 2025 Direct F2
transaction AKYA Common Stock Other -947,688 -100% 0 08 Jul 2025 Direct F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKYA Employee Stock Option (Right to Buy) Other $0 -393,338 -100% $0.000000 0 08 Jul 2025 Common Stock 393,338 $0.3029 Direct F1, F2
transaction AKYA Employee Stock Option (Right to Buy) Other $0 -331,090 -100% $0.000000 0 08 Jul 2025 Common Stock 331,090 $0.4427 Direct F1, F2
transaction AKYA Employee Stock Option (Right to Buy) Other $0 -241,592 -100% $0.000000 0 08 Jul 2025 Common Stock 241,592 $16.12 Direct F5, F6
transaction AKYA Employee Stock Option (Right to Buy) Other $0 -160,000 -100% $0.000000 0 08 Jul 2025 Common Stock 160,000 $11.88 Direct F5, F6
transaction AKYA Employee Stock Option (Right to Buy) Other $0 -160,000 -100% $0.000000 0 08 Jul 2025 Common Stock 160,000 $12.30 Direct F5, F6
transaction AKYA Employee Stock Option (Right to Buy) Other $0 -175,000 -100% $0.000000 0 08 Jul 2025 Common Stock 175,000 $5.35 Direct F5, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Brian McKelligon is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Cashless exercise of options pursuant to that certain Amended and Restated Agreement and Plan of Merger dated as of April 28, 2025, as amended (the "Merger Agreement"), by and among Quanterix Corporation, a Delaware corporation ("Quanterix"), Wellfleet Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Quanterix ("Merger Sub"), and the Issuer. On July 8, 2025 (the "Closing Date"), Merger Sub merged with and into Issuer (the "Merger"), with Issuer surviving the Merger as a wholly owned subsidiary of Quanterix.
F2 Pursuant to the Merger Agreement, as of the Closing Date, each outstanding option to purchase Issuer common stock was accelerated and each option with a per share exercise price less than the value of the Per Share Merger Consideration (as defined below) was automatically cashless exercised.
F3 Disposition of shares pursuant to Merger Agreement.
F4 In connection with the terms of the Merger Agreement, each share of common stock of Issuer outstanding on the Closing Date was converted into the right to receive (a) 0.1461 of a share of common stock of Quanterix (the "Per Share Stock Consideration") and (b) $0.38 in cash, without interest (the "Per Share Cash Consideration" and together with the Per Share Stock Consideration, the "Per Share Merger Consideration"). Each of the Per Share Stock Consideration and the Per Share Cash Consideration may be adjusted pursuant to the terms of the Merger Agreement.
F5 Disposition of options pursuant to the Merger Agreement.
F6 Pursuant to the Merger Agreement, as of the Closing Date, each outstanding option to purchase Issuer common stock was accelerated and each option with a per share exercise price equal to or greater than the Per Share Merger Consideration was automatically terminated and cancelled for no consideration.